{"denoms":[{"counts":[{"groupId":"BG000","value":"6"},{"groupId":"BG001","value":"13"},{"groupId":"BG002","value":"13"},{"groupId":"BG003","value":"36"},{"groupId":"BG004","value":"3"},{"groupId":"BG005","value":"10"},{"groupId":"BG006","value":"6"},{"groupId":"BG007","value":"14"},{"groupId":"BG008","value":"35"},{"groupId":"BG009","value":"136"}],"units":"Participants"}],"groups":[{"description":"Dose Escalation, 7 or 12 µg/kg/day of Tagraxofusp as IV over 15 minutes for up to 5 consecutive days of a 21-day cycle","id":"BG000","title":"First-line BPDCN- Stage 1"},{"description":"Administration of 12 µg/kg/day of Tagraxofusp as IV over 15 minutes for up to 5 consecutive days of a 21-day cycle","id":"BG001","title":"First-line BPDCN - Stage 2"},{"description":"Administration of 12 µg/kg/day of Tagraxofusp as IV over 15 minutes for up to 5 consecutive days of a 21-day cycle","id":"BG002","title":"First-line BPDCN - Stage 3"},{"description":"Administration of 12 µg/kg/day of Tagraxofusp as IV over 15 minutes for up to 5 consecutive days of a 21-day cycle","id":"BG003","title":"First-line BPDCN - Stage 4"},{"description":"Dose Escalation, 12 µg/kg/ day of Tagraxofusp as IV over 15 minutes for up to 5 consecutive days of a 21-day cycle","id":"BG004","title":"R/R BPDCN - Stage 1"},{"description":"Administration of 12 µg/kg/day of Tagraxofusp as IV over 15 minutes for up to 5 consecutive days of a 21-day cycle","id":"BG005","title":"R/R BPDCN - Stage 2"},{"description":"Administration of 12 µg/kg/day of Tagraxofusp as IV over 15 minutes for up to 5 consecutive days of a 21-day cycle","id":"BG006","title":"R/R BPDCN - Stage 4"},{"description":"Dose Escalation 7, 9,12 or 16 µg/kg/ day of Tagraxofusp as IV over 15 minutes for up to 5 consecutive days of a 21-day cycle","id":"BG007","title":"AML - Stage 1"},{"description":"Administration of 12 µg/kg/ day of Tagraxofusp as IV over 15 minutes for up to 5 consecutive days of a 21-day cycle","id":"BG008","title":"AML - Stage 2"},{"description":"Total of all reporting groups","id":"BG009","title":"Total"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"10.49","value":"67"},{"groupId":"BG001","spread":"17.72","value":"62.5"},{"groupId":"BG002","spread":"17.15","value":"61.7"},{"groupId":"BG003","spread":"14.71","value":"64.1"},{"groupId":"BG004","spread":"7.94","value":"72"},{"groupId":"BG005","spread":"9.31","value":"69.7"},{"groupId":"BG006","spread":"15.32","value":"67.5"},{"groupId":"BG007","spread":"11.17","value":"58.6"},{"groupId":"BG008","spread":"16.01","value":"61.2"},{"groupId":"BG009","spread":"14.64","value":"63.4"}]}]}],"dispersionType":"STANDARD_DEVIATION","paramType":"MEAN","title":"Age, Continuous","unitOfMeasure":"years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"3"},{"groupId":"BG002","value":"2"},{"groupId":"BG003","value":"7"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"2"},{"groupId":"BG006","value":"1"},{"groupId":"BG007","value":"7"},{"groupId":"BG008","value":"13"},{"groupId":"BG009","value":"36"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"5"},{"groupId":"BG001","value":"10"},{"groupId":"BG002","value":"11"},{"groupId":"BG003","value":"29"},{"groupId":"BG004","value":"3"},{"groupId":"BG005","value":"8"},{"groupId":"BG006","value":"5"},{"groupId":"BG007","value":"7"},{"groupId":"BG008","value":"22"},{"groupId":"BG009","value":"100"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"5"},{"groupId":"BG001","value":"12"},{"groupId":"BG002","value":"13"},{"groupId":"BG003","value":"30"},{"groupId":"BG004","value":"2"},{"groupId":"BG005","value":"10"},{"groupId":"BG006","value":"5"},{"groupId":"BG007","value":"12"},{"groupId":"BG008","value":"31"},{"groupId":"BG009","value":"120"}]}],"title":"White"},{"categories":[{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"6"},{"groupId":"BG004","value":"1"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"1"},{"groupId":"BG007","value":"2"},{"groupId":"BG008","value":"4"},{"groupId":"BG009","value":"16"}]}],"title":"Other"}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Race/Ethnicity, Customized","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"3"},{"groupId":"BG001","value":"6"},{"groupId":"BG002","value":"8"},{"groupId":"BG003","value":"16"},{"groupId":"BG004","value":"1"},{"groupId":"BG005","value":"4"},{"groupId":"BG006","value":"2"},{"groupId":"BG007","value":"5"},{"groupId":"BG008","value":"6"},{"groupId":"BG009","value":"51"}]}],"title":"ECOG 0"},{"categories":[{"measurements":[{"groupId":"BG000","value":"3"},{"groupId":"BG001","value":"7"},{"groupId":"BG002","value":"5"},{"groupId":"BG003","value":"17"},{"groupId":"BG004","value":"2"},{"groupId":"BG005","value":"6"},{"groupId":"BG006","value":"4"},{"groupId":"BG007","value":"8"},{"groupId":"BG008","value":"26"},{"groupId":"BG009","value":"78"}]}],"title":"ECOG 1"},{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"2"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"0"},{"groupId":"BG007","value":"1"},{"groupId":"BG008","value":"2"},{"groupId":"BG009","value":"5"}]}],"title":"ECOG 2"},{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"1"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"0"},{"groupId":"BG007","value":"0"},{"groupId":"BG008","value":"1"},{"groupId":"BG009","value":"2"}]}],"title":"Missing"}],"description":"Grade 0 Able to carry out all normal activities without restriction.\n\nGrade 1 Restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature.\n\nGrade 2 Ambulatory and capable of all self-care but unable to carry out any work activities: up and about more than 50% of waking hours.\n\nGrade 3 Capable of limited self-care; confined to bed or chair more than 50% of waking hours.\n\nGrade 4 Completely disabled; cannot carry on self-care; totally confined to bed or chair.","paramType":"COUNT_OF_PARTICIPANTS","title":"ECOG Performance Status Scale","unitOfMeasure":"Participants"}],"populationDescription":"modified ITT (mITT): all patients with blastic plasmacytoid dendritic cell neoplasm (first-line or relapsed/refractory) and acute myeloid leukemia who were eligible based on the screening criteria and who received at least 1 dose of tagraxofusp, excluding 2 patients who withdrew from study before first response assessment. Total mITT=136. Baseline characteristics data collected by disease and study stage only."}